Nuclear receptors are drug targets of no less than 16% of clinically used small-molecule drugs. Side effects prevent the exploitation of their full potential. The De Bosscher lab focuses on understanding how nuclear receptors transduce signals when triggered by different ligands and how different nuclear receptor signaling pathways interact, referred to as “crosstalk”. Our goal is to decipher these crosstalk mechanisms as a first step towards innovative nuclear receptor-targeting strategies with enhanced therapeutic benefits. In addition, we develop novel cell-based tools that enable capturing nuclear receptors’ complexity and aim at translating to drug discovery platforms.